10/15/25 16:05 | 10/14/25 | VNRX | Volitionrx Ltd | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Reynolds Cameron John | NV | DO | P,CEO | 3 | P.d | 116 | 0.5710 | 0 | 203 | 6 | 3,667 | D | | | | | | | | | | | | | | |
10/15/25 16:05 | 10/14/25 | VNRX | Volitionrx Ltd | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Innes Guy Archibald | NV | D | | 2 | P.d | 99 | 0.5683 | 0 | 174 | 5 | 3,437 | D | | | | | | | | | | | | | | |
10/15/25 16:05 | 10/14/25 | VNRX | Volitionrx Ltd | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Still Timothy I | NV | D | | 1 | P.d | 25 | 0.5100 | 0 | 48 | 3 | 1,535 | D | | | | | | | | | | | | | | |
10/14/25 15:35 | 10/13/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Rocklin Amy M | MI | O | GC | 3 | M.d | 106 | 5.41 | 0 | 20 | 65 | 50 | D | | | | | | | | | | | | | | |
10/14/25 15:24 | 10/13/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Jones Douglas Edward | MI | O | Former C | 3 | M.d | 155 | 5.54 | 0 | 28 | 46 | 89 | D | | | | | | | | | | | | | | |
10/14/25 14:59 | 10/13/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Adent John Edward | MI | O | Former C | 3 | M.d | 398 | 5.55 | 0 | 72 | 27 | 333 | D | | | | | | | | | | | | | | |
10/9/25 17:03 | 10/7/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Woteki Catherine E | MI | D | | 1 | M.d | 12 | 5.63 | 0 | 2 | 16 | 15 | D | | | | | | | | | | | | | | |
10/9/25 17:00 | 10/7/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Tobin James P | MI | D | | 1 | M.d | 12 | 5.63 | 0 | 2 | 6 | 40 | D | | | | | | | | | | | | | | |
10/9/25 16:58 | 10/7/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Rodriguez Rafael A | MI | D | | 1 | M.d | 12 | 5.63 | 0 | 2 | 14 | 17 | D | | | | | | | | | | | | | | |
10/9/25 16:54 | 10/7/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Gupta Aashima | MI | D | | 1 | M.d | 12 | 5.63 | 0 | 2 | 9 | 24 | D | | | | | | | | | | | | | | |
10/9/25 16:51 | 10/7/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Green Ronald D | MI | D | | 1 | M.d | 12 | 5.63 | 0 | 2 | 16 | 15 | D | | | | | | | | | | | | | | |
10/9/25 16:48 | 10/7/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Capello Jeffrey D | MI | D | | 1 | M.d | 12 | 5.63 | 0 | 2 | 8 | 29 | D | | | | | | | | | | | | | | |
10/9/25 16:44 | 10/7/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Borel James C | MI | D | | 1 | M.d | 12 | 5.63 | 0 | 2 | 2 | 93 | D | | | | | | | | | | | | | | |
10/9/25 16:36 | 10/7/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Boehm William T | MI | D | | 1 | M.d | 12 | 5.63 | 0 | 2 | 6 | 38 | D | | | | | | | | | | | | | | |
10/3/25 17:13 | 10/1/25 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Schultes Birgit C | MA | O | EVP,Chie | 1 | S | -1 | 17.39 | 0 | 0 | 0 | 105 | D | | | | | | | | | | | | | | |
10/3/25 17:13 | 10/1/25 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Dube Michael P | MA | O | VP,Chief | 1 | S | -33 | 17.38 | 0 | -2 | | 55 | D | | | | | | | | | | | | | | |
10/1/25 16:55 | 9/30/25 | IONS | Ionis Pharmaceuticals Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hougen Elizabeth L | CA | O | EVP,Fina | 2 | M.d | 5,927 | 59.51 | 0 | 100 | 914 | 111 | D | | | | | | | | | | | | | | |
10/1/25 16:55 | 9/30/25 | IONS | Ionis Pharmaceuticals Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hougen Elizabeth L | CA | O | EVP,Fina | 2 | S.d | -5,927 | 59.51 | 0 | -100 | | 111 | D | | | | | | | | | | | | | | |
9/22/25 16:31 | 9/18/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Oki Mark K | WA | O | CFO | 2 | M.d | 146 | 0.6703 | 0 | 218 | | 128 | D | | | | | | | | | | | | | | |
9/22/25 16:31 | 9/18/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Oki Mark K | WA | O | CFO | 2 | S.d | -146 | 0.6703 | 0 | -218 | | 128 | D | | | | | | | | | | | | | | |
9/22/25 16:29 | 9/18/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Stewart Richard Alistair | WA | DO | CEO | 2 | M.d | 378 | 0.8856 | 0 | 427 | | 230 | D | | | | | | | | | | | | | | |
9/22/25 16:29 | 9/18/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Stewart Richard Alistair | WA | DO | CEO | 2 | S.d | -378 | 0.8856 | 0 | -427 | | 230 | D | | | | | | | | | | | | | | |
9/19/25 17:26 | 9/17/25 | AWHL | Aspira Women'S Health Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Schuler Jack W | | T | | 1 | P.d | 500 | 0.4500 | 0 | 1,111 | 41 | 3,830 | I | | | | | | | | | | | | | | |
9/19/25 17:26 | 9/17/25 | AWHL | Aspira Women'S Health Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Cohen Jeffrey K | | D | | 1 | P.d | 25 | 0.4500 | 0 | 56 | 15 | 437 | I | | | | | | | | | | | | | | |
9/19/25 16:05 | 9/17/25 | AWHL | Aspira Women'S Health Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Fraser John D | PA | D | | 1 | P.d | 7 | 0.4500 | 0 | 16 | 2 | 858 | D | | | | | | | | | | | | | | |
9/8/25 16:59 | 9/4/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Wan Jerry | A1 | O | Principa | 2 | M.d | 39 | 0.8091 | 0 | 48 | | 33 | D | | | | | | | | | | | | | | |
9/8/25 16:59 | 9/4/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Wan Jerry | A1 | O | Principa | 2 | S.d | -39 | 0.8091 | 0 | -48 | | 33 | D | | | | | | | | | | | | | | |
9/8/25 16:54 | 9/4/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | King Thomas Braxton | WA | D | | 2 | M.d | 387 | 0.6513 | 0 | 595 | | 315 | D | | | | | | | | | | | | | | |
9/8/25 16:54 | 9/4/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | King Thomas Braxton | WA | D | | 2 | S.d | -387 | 0.6513 | 0 | -595 | | 315 | D | | | | | | | | | | | | | | |
9/8/25 16:51 | 9/4/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Jacobs Cindy | WA | O | P,CMO | 2 | M.d | 77 | 0.5561 | 0 | 138 | | 116 | D | | | | | | | | | | | | | | |
9/8/25 16:51 | 9/4/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Jacobs Cindy | WA | O | P,CMO | 2 | S.d | -77 | 0.5561 | 0 | -138 | | 116 | D | | | | | | | | | | | | | | |
9/8/25 16:39 | 9/4/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Xinos Jaime | WA | O | Chief Co | 2 | M.d | 58 | 0.6429 | 0 | 90 | | 74 | D | | | | | | | | | | | | | | |
9/8/25 16:39 | 9/4/25 | ACHV | Achieve Life Sciences, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Xinos Jaime | WA | O | Chief Co | 2 | S.d | -58 | 0.6429 | 0 | -90 | | 74 | D | | | | | | | | | | | | | | |
9/3/25 17:56 | 9/1/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Smith Martin Alexander | ME | O | EVP | 1 | M.d | 0 | 0.00 | 0 | 0 | 1 | 1 | D | | | | | | | | | | | | | | |
8/22/25 16:30 | 8/20/25 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Chase William J | MA | D | | 1 | P | 1,003 | 10.03 | 0 | 100 | 288 | 135 | D | | | | | | | | | | | | | | |
8/21/25 17:27 | 8/19/25 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Patel Rajiv A | CA | H | Member o | 1 | S.m | -191,214 | 56.14 | 0 | -3,406 | | 3,477 | I | | | | | | | | | | | | | | |
8/21/25 17:27 | 8/19/25 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Farallon Partners L L C/Ca | CA | TH | Member o | 1 | S.m | -191,214 | 56.14 | 0 | -3,406 | | 3,477 | I | | | | | | | | | | | | | | |
8/20/25 11:57 | 8/18/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Naemura David H. | MI | O | CFO | 1 | M.d | 78 | 5.43 | 0 | 14 | 26 | 70 | D | | | | | | | | | | | | | | |
8/20/25 10:23 | 8/18/25 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Moylan John Patrick | MI | O | Chief Ac | 1 | M.d | 11 | 5.43 | 0 | 2 | 16 | 14 | D | | | | | | | | | | | | | | |
8/15/25 16:33 | 8/13/25 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | P | 1 | S | -164 | 53.57 | 0 | -3 | | 108 | D | | | | | | | | | | | | | | |
8/15/25 16:07 | 8/13/25 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Jimenez Freddy A. | NJ | O | SVP,GC | 1 | S | -19 | 24.77 | 0 | -1 | | 35 | D | | | | | | | | | | | | | | |
8/14/25 18:01 | 8/12/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Erickson Michael G | ME | O | EVP | 1 | S | -264 | 649.79 | 0 | 0 | | 11 | D | | | | | | | | | | | | | | |
8/13/25 17:17 | 8/11/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hunt Nimrata | ME | O | EVP | 4 | S.d | -7,990 | 357.29 | 0 | -22 | | 18 | D | | | | | | | | | | | | | | |
8/13/25 17:17 | 8/12/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hunt Nimrata | ME | O | EVP | 4 | M.d | 7,990 | 357.29 | 0 | 22 | | 18 | D | | | | | | | | | | | | | | |
8/12/25 17:00 | 8/8/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Underberg Sharon E. | ME | O | EVP,GC,C | 2 | M.dm | 4,779 | 431.17 | 0 | 11 | | 6 | D | | | | | | | | | | | | | | |
8/12/25 17:00 | 8/8/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Underberg Sharon E. | ME | O | EVP,GC,C | 2 | S.dm | -4,779 | 431.17 | 0 | -11 | | 6 | D | | | | | | | | | | | | | | |
8/12/25 17:00 | 8/8/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Mazelsky Jonathan Jay | ME | DO | P,CEO | 3 | M.d | 20,586 | 350.69 | 0 | 59 | 237 | 83 | D | | | | | | | | | | | | | | |
8/11/25 18:00 | 8/7/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Emerson Andrew | ME | O | EVP,CFO, | 1 | M.d | 262 | 141.60 | 0 | 2 | 91 | 4 | D | | | | | | | | | | | | | | |
8/8/25 20:37 | 8/6/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lane Michael | ME | O | EVP | 2 | M.d | 7,604 | 452.00 | 0 | 17 | | 8 | D | | | | | | | | | | | | | | |
8/8/25 20:37 | 8/6/25 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lane Michael | ME | O | EVP | 2 | S.d | -7,604 | 452.00 | 0 | -17 | | 8 | D | | | | | | | | | | | | | | |
7/25/25 16:05 | 7/23/25 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Dulac Edward J III | MA | O | EVP,CFO | 1 | S | -105 | 14.02 | 0 | -7 | | 106 | D | | | | | | | | | | | | | | |